Inventiva Pharma

Beleggen in aandelenbeurzen Europa: DAX, FTSE 100, CAC40, etc.

Beleggen met ongekend lage tarieven?
Aandelen BE/NL €2+0,03% / VS €0,50+$0,004 p/st
Kernselectie: Geen kosten turbo's, ETF's en fondsen
DEGIRO: meer informatie / rekening openen


Gebruikersavatar
Lama Daila
Forum elite
Forum elite
Berichten: 2327
Lid geworden op: 20 jul 2017 10:53
waarderingen: 4497
Contacteer:

Re: Inventiva Pharma

Bericht door Lama Daila »

VWarena schreef:
18 feb 2021 19:21
Serieuze dip? Surfen op de golfen van een biotech'er ;)
52 weken ...2,36 :arrow: 16,30 :clap:

Geen paniek, momenteel zowat alles in 't rood. Gezonde correctie, wat lucht eruit laten na een recente ATH ...
Wachten nu op de AbbVie results fase 1 die ons boloofd zijn in Q1 21
AbbVie heeft zelf al meegegeven dat die resultaten er pas zullen zijn in Q2.
beursfre liked last!
https://twitter.com/lama_daila





VWarena
Forum veteraan
Forum veteraan
Berichten: 1025
Lid geworden op: 04 jun 2015 13:46
waarderingen: 653
Contacteer:

Re: Inventiva Pharma

Bericht door VWarena »

@ Lama Daila... Dank voor uw correctie :up:

Soppi
Forum actieveling
Forum actieveling
Berichten: 511
Lid geworden op: 20 dec 2012 09:04
waarderingen: 515
Contacteer:

Re: Inventiva Pharma

Bericht door Soppi »

Inventiva’s 2020 Full-Year Financial Results Presentation


Daix (France), February 23, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that its management team will host a webcast to present the Company’s full-year financial results for 2020 on Friday, March 5, 2021.

Inventiva’s 2020 full-year financial results will be released on Thursday, March 4, 2021 at 4:00 pm (New York), 10:00 pm (Paris).

Frédéric Cren, Chairman, CEO and cofounder of Inventiva, Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, Jean Volatier, Chief Financial Officer of Inventiva, and Michael Cooreman, Chief Medical Officer of Inventiva, will hold a conference call in English, followed by a Q&A session, on Friday, March 5, 2021 at 8:00 am (New York), 2:00 pm (Paris).

The conference call and the slides of the presentation will be webcast live at: https://edge.media-server.com/mmc/p/wr8srgzq and also available on Inventiva’s onwards in the “Investors” – “Financial results” section.


To join the conference call, please use the code 3586531 after dialing one of the following numbers:

France: +33 (0) 1 70 70 07 81
Belgium: +32 (0) 2 793 3847
Germany: +49 (0) 69 2222 2625
Netherlands: +31 (0) 20 795 6614
Switzerland: +41 (0) 44 580 7145
United Kingdom: +44 (0) 207 192 8338
United States: +1 646-741-3167


Please note that the line will be opened 10 minutes before the start of the conference call.

A replay of the conference call and the presentation will be available after the event at: http://inventivapharma.com/investors/fi ... entations/
Gekko liked last!

Gebruikersavatar
ZyppBe
Forum gebruiker
Forum gebruiker
Berichten: 200
Lid geworden op: 07 sep 2020 14:59
waarderingen: 290
Contacteer:

Re: Inventiva Pharma

Bericht door ZyppBe »

Inventiva announces collaboration on non-invasive biomarkers to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvemen

The Company will collaborate with Professor Jérôme Boursier, M.D., Ph.D, a renowned scientist in the field of non-invasive diagnosis of liver lesions in chronic liver diseases

► The collaboration aims at developing one or several biomarkers or a composite biomarker score to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvement

► The biomarker data from the NATIVE Phase IIb clinical trial with lanifibranor in NASH will be used as a first validation dataset and the lanifibranor biomarker signature would then be validated during upcoming NATIV3 Phase III clinical trial



Daix (France), February 25, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced a collaboration in the field of NASH biomarkers with Professor Jérôme Boursier, M.D., Ph.D, Professor of Medicine at the Faculty of Medicine of Angers University and renowned scientist in the area of non-invasive diagnosis of liver lesions in chronic liver diseases.

The objective of the collaboration is to develop one or several biomarkers or a composite biomarker score to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvement. More specifically, Professor Jérôme Boursier, M.D., Ph.D, and his team from the HIFIH1 Laboratory (UPRES EA3859, Angers University) will use a multivariate statistical approach to finding a biomarker signature of lanifibranor in NASH treatment.

As part of this collaboration, the database from Inventiva’s NATIVE Phase IIb clinical trial evaluating lanifibranor for the treatment of NASH and containing a list of around 80 biomarkers will be used as a first validation dataset. The selected biomarker(s) or biomarker composite score would then be validated during the upcoming NATIV3 (NASH lanifibranor Phase III trial) Phase III clinical trial with lanifibranor in NASH, the initiation of which is planned for the first half of 2021. As a reminder, several analyses of biomarkers and other non-invasive tests based on the results from the NATIVE Phase IIb trial had shown promising treatment effects of lanifibranor versus placebo and were presented during a webcast event from The Liver Meeting Digital Experience™ 2020 on November 16, 2020.2

Pierre Broqua, CSO and cofounder of Inventiva, commented: “With an increasing number of patients developing NASH-related end-stage liver disease and pharmacological treatments on the horizon, there is a pressing need to develop NASH biomarkers for prognostication, patient selection and treatment monitoring. We are therefore very excited to start this collaboration with Professor Jérôme Boursier and his team, who have been extensively involved in the development of non-invasive tests to diagnose NASH patients over the past years. Developing a non-invasive biomarker signature to identify responders to lanifibranor is totally in line with our strategy to make our lead drug candidate a reference treatment for NASH patients.”

Jérôme Boursier, M.D., Ph.D., Professor of Medicine at the Faculty of Medicine of Angers University, stated: “The need to develop reliable NASH biomarkers is both clear and urgent as the utility of liver biopsy, the only diagnostic approach currently available, is limited due to its invasive nature, poor patient acceptability and sampling variability. So we are very much looking forward to working with Inventiva on lanifibranor, a drug candidate that has shown very promising results in the field of NASH. Given the efficacy shown by lanifibranor during the NATIVE Phase IIb trial and the promising biomarker dataset available, we are confident that we will be able to meet our objective to develop one or several robust biomarkers or composite biomarker score.”


Biography – Jérôme Boursier

Jérôme Boursier, M.D., Ph.D., is Professor of Medicine at the Faculty of Medicine of Angers University, France. His main field of research covers the non-invasive diagnosis of liver lesions in chronic liver diseases, especially Non-Alcoholic Fatty Liver Disease (NAFLD). In parallel, Professor Boursier heads the HIFIH Laboratory (UPRES EA3859, SFR 4208) at Angers University and the Department of Hepato-Gastroenterology and Digestive Oncology at Angers University Hospital. Graduated from the Faculty of Medicine of Angers University, his Ph.D work focused on methodology to improve the accuracy of the non-invasive diagnosis of liver fibrosis in chronic hepatitis C. In the context of a research fellowship at the Anna Mae Diehl Lab of Duke University, Durham, United States, Professor Boursier investigated in the area of the gut microbiota and NAFLD. He currently leads many studies about the diagnosis, screening and prognosis assessment in NAFLD.
Gekko liked last!
ABI / ACPH / ADBE / BABA / ESPO / GLPG / INGA / IVA / KHOOT / LFMD / PAVM / PHARM / PLTR / PNL / PRX / SQ / TDOC / U

Gebruikersavatar
Gekko
Forum gebruiker
Forum gebruiker
Berichten: 140
Lid geworden op: 02 mar 2018 20:24
waarderingen: 130

Re: Inventiva Pharma

Bericht door Gekko »

Conférence n°1:«Credit Suisse Virtual 2021 London Global Healthcare Conference» 2-4 mars 2021

2:«H.C. Wainwright Virtual Global Life Sciences Conference» : 9 mars

3:«33rd Virtual Annual Roth Conference : 15 mars

Gebruikersavatar
ZyppBe
Forum gebruiker
Forum gebruiker
Berichten: 200
Lid geworden op: 07 sep 2020 14:59
waarderingen: 290
Contacteer:

Re: Inventiva Pharma

Bericht door ZyppBe »

Update Bolero Benelux Selectie (KBCS)

Inventiva (ISIN: FR0013233012)

KBC Securities: “Kopen”-advies – koersdoel 28,00 euro
Opwaarts potentieel: 120,50% (tegenover slotkoers 03/03/2021)

Analist Lenny Van Steenhuyse: “Eind juni publiceerde Inventiva resultaten voor zijn klinische NATIVE-studie in fase IIb met Lanifibranor bij NASH-patiënten (niet-alcoholische leverontsteking), waaruit bleek dat het middel een topkandidaat is in de race naar de NASH-markt.

Inventiva handelt met een flinke korting tegenover Amerikaanse beursgenoteerde sectorgenoten wiens studie zich nog in een vroeger stadium bevindt of die inferieure resultaten boeken (marktkapitalisatie IVA 593 miljoen dollar, Madrigal 1.769 miljoen dollar, Akero 1.042 miljoen dollar, NGM Bio 2.008 miljoen dollar). Met resultaten die tot de beste van de klas behoren in NASH-therapeutica en aangevulde cashreserves na zijn recente beursgang op NASDAQ zit Inventiva in een sterke positie om gesprekken op te starten rond partnering om Lanifibranor verder te ontwikkelen in fase III klinische studies.”
Gekko liked last!
ABI / ACPH / ADBE / BABA / ESPO / GLPG / INGA / IVA / KHOOT / LFMD / PAVM / PHARM / PLTR / PNL / PRX / SQ / TDOC / U

Terugnajaren
Forum actieveling
Forum actieveling
Berichten: 302
Lid geworden op: 19 jul 2019 13:50
waarderingen: 383
Contacteer:

Re: Inventiva Pharma

Bericht door Terugnajaren »

kakelverse PB;

2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States


Publication of positive topline results from the NATIVE Phase IIb clinical trial evaluating lanifibranor in NASH and decision to move into pivotal Phase III development
► Breakthrough Therapy Designation granted to lanifibranor in NASH by the U.S. Food and Drug Administration (FDA)
► Finalization of Phase III clinical trial design with lanifibranor in NASH following end-of-phase II meeting with the FDA and receipt of Scientific Advice letter from the European Medicines Agency (EMA)
► Expansion into the United States with appointment of Dr. Michael Cooreman, M.D., as Chief Medical Officer and opening of U.S. subsidiary
► Announcement of timeline for Phase III clinical trial evaluating lanifibranor in NASH
► Confirmation by the FDA that the toxicology package regarding lanifibranor is complete and acceptable to support the filing of a New Drug Application (NDA) for the treatment of NASH and improvement of liver fibrosis
► Completion of World Health Organization’s (WHO) International Nonproprietary Names (INN) process by AbbVie for ABBV-157, now named cedirogant
► Cash position1 at €113.0m as of December 31, 2020 compared to €35.8m as of December 31, 2019
► Successful €94.9m2 initial public offering (IPO) on the Nasdaq Global Market in the U.S, extending the Company’s cash runway through Q4 2022

Daix (France), March 4, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today reported its full-year results for 2020.
Frédéric Cren, Chairman, CEO and cofounder of Inventiva, stated: “2020 has truly been one of the most transformative years since the establishment of Inventiva in 2012, driven by a series of major achievements. Following very promising results from our NATIVE Phase IIb clinical trial in NASH and the U.S. FDA ‘Breakthrough Therapy’ designation of lanifibranor, the FDA and EMA have given us their green light to initiate the pivotal Phase III trial with our lead drug candidate, the design of which we have finalized in the beginning of this year. Based on these milestones, clearly confirming the potential of lanifibranor to become a reference treatment for NASH, we have decided to focus our efforts on this particular program while, in parallel, evaluating all options to optimize the development of our second clinical-stage asset odiparcil in MPS VI. At the same time, we were able to significantly extend our cash runway and boost our visibility in the United States thanks to the success of our IPO on the Nasdaq Global Market. Together with the appointment of Dr. Michael Cooreman as Chief Medical Officer and the very recent opening of Inventiva’s subsidiary in the United States, we are on track to initiate the Phase III clinical trial with lanifibranor in NASH in the first half of this year.”

Key financial results
Inventiva’s key financial figures for its 2020 full-year results are as follows:
As of December 31, 2020, the Company’s cash position3 (excluding exchange rate effects) stood at €113.0 million compared to €124.6 million as of September 30, 2020, and €35.8 million as of December 31, 2019.
• In 2020, net cash used in operating activities amounted to (€30.6) million compared to (€28.4) million in 2019. This increase was mainly due to higher general and administrative and non-recurrent expenses incurred during the second half of the year linked to the Company’s IPO in the U.S. and listing on Nasdaq. These costs have been partly offset by the savings generated from the halt of the clinical development of lanifibranor in systemic sclerosis in 2019 and the Employment Safeguard Plan subsequently introduced mid-2019, as well as, to a lesser extent, the successful conclusion of the NATIVE Phase IIb clinical study in NASH in June 2020. Furthermore, the cash flow from operating activities was positively impacted by the receipt of €4.2 million in respect of the 2018 Research Tax Credit (CIR - Crédit Impôt Recherche) in January 2020, and the receipt of €4.2 million in total in respect of the 2019 Research Tax Credit in April and June 2020. In 2019, Inventiva recorded the payment of €3.6 million of the 2017 Research Tax Credit, the €3.5 million milestone payment from AbbVie following the enrollment of the first psoriasis patient in the clinical study underway with ABBV-157 and the last payment from Boehringer Ingelheim as part of its collaboration with the Company.

• Net cash from investing activities (excluding the variation in short-term deposits) remained stable in 2020 compared to 2019 and amounted to (€0.9) million.

• Finally, net cash from financing activities amounted to €111.7 million in 2020 compared to €8.4 million in 2019, driven by: the issuance of €15.0 million (gross proceeds) of ordinary shares to certain existing investors in the Company in February 2020, the entry into a €10.0 million credit agreement, guaranteed by the French State, with a syndicate of French banks in May 2020, and the receipt of €94.9 million4 (gross proceeds) following the Company’s successful U.S. IPO in July 2020, extending Inventiva’s cash runway through the fourth quarter of 2022.

In 2020, Inventiva's revenues amounted to €0.4 million compared to €7.0 million in 2019.While Inventiva did not expect to generate any revenues in 2020, this decrease was driven by the Company recording the payment of €3.5 million under its collaboration with AbbVie in December 2019, the revenues of €2.6 million under its collaboration with Boehringer Ingelheim in November 2019, including the payment of €0.5 million and the €2.1 million write back entry, in accordance with IFRS 15 "Revenue from Contracts with Customer", following the end of this research collaboration after Inventiva fulfilled all its commitments.
Other income amounted to €4.9 million in 2020 versus €4.3 million in 2019, up 14%, mainly driven by the receipt of the 2018 and 2019 Research Tax Credit.
R&D expenses amounted to €23.7 million in 2020 versus €33.8 million in 2019, down 29%. These expenses were mainly dedicated to the development of lanifibranor in NASH and odiparcil in MPS VI. The decrease compared to the previous year was mainly due to the halt of the clinical development of lanifibranor in systemic sclerosis in February 2019 and the savings generated by the Employment Safeguard Plan subsequently introduced, with 2020 recording the full effect of the savings generated. In addition, while the Company had recorded R&D expenses related to the NATIVE Phase IIb clinical trial in NASH for the entire fiscal year in 2019, Inventiva did not record as significant clinical development expenses in the second half of 2020 as in the first half of 2020 given the successful conclusion of the NATIVE Phase IIb trial in June 2020.
General and administrative expenses amounted to €8.5 million in 2020 compared to €6.1 million in 2019, primarily driven by expenses related to the preparation of the Company’s IPO in the U.S. and the increased operational recurring expenses linked to Inventiva’s dual listing status following its listing on Nasdaq.
Other operating income (expenses) amounted to €2.2 million in 2020 compared to €1.5 million in 2019. The first half of 2019 took into account the recording of a provision of €1.1 million relating to the Employment Safeguard Plan, while 2020 recorded non-recurring expenses incurred as part of the IPO in the U.S., not reflected in the share premium of issued shares, and a non-recurring net income related to the Research Tax Credit of previous years.
Due to the unfavourable exchange rate between USD and Euro following the Company’s IPO in the U.S. and listing on Nasdaq in July 2020, Inventiva has incurred a net financial loss of €3.9 million.
The Company’ net loss stood at €33.6 million in 2020 compared to a loss of €30.2 million in 2019.
The following table presents Inventiva’s income statement, prepared in accordance with IFRS, for the 2020 financial year, with comparatives for the 2019 financial year:
(in thousands of euros, except share and per share amounts) December 31,
2020 December 31,
2019
Revenues 372 6,998
Other income 4,891 4,293
Research and development expenses (23,717) (33,791)
Marketing – business development expenses (563) (249)
General and administrative expenses (8,499) (6,088)
Other operating income (expenses) (2,202) (1,475)
Net operating loss (29,718) (30,312)
Net financial income (loss) (3,902) 93
Income tax - -
Net loss for the period (33,619) (30,218)
Basic / diluted loss per share (euros/share) (0.99) (1.28)
Weighted average number of outstanding shares used for computing basic/diluted loss per share 33,874,751 23,519,897


Announcement of the timeline for the Phase III clinical trial with lanifibranor in NASH
Inventiva is progressing on the initiation of its NATIV3 (NASH lanifibranor Phase 3 trial) Phase III clinical trial evaluating lanifibranor in NASH, and has defined the following timeline for Part 1 of the study5:
 First site active – expected for the second quarter of 2021
 First Patient First Visit – expected in the third quarter of 2021
 Last Patient First Visit – expected in the second half of 2022
 Last Patient Last Visit – expected in the first half of 2024
 Publication of headline results – expected in the second half of 2024

Update on non-clinical toxicology data regarding lanifibranor
During a type B meeting with the FDA, the regulatory body has confirmed that the non-clinical toxicology package available for lanifibranor is both complete and acceptable to support the filing of a NDA for the targeted indication of treatment of NASH and improvement of liver fibrosis. The package includes the results of two-year carcinogenicity studies in mice and rats as well as long-term toxicology studies of up to one year in monkeys.

Update of the timeline for the Phase II clinical trial with lanifibranor in type 2 diabetes patients (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)
The COVID-19 pandemic has had a large impact on patient enrollment during 2020. In this context, the publication of the study results are now expected in the first half of 2022 versus 2021 as previously announced.

Update on the collaboration with AbbVie in auto-immune diseases
Following the completion of the WHO INN process by AbbVie, the name of “cedirogant” has been attributed to ABBV-157, the selective and orally-available ROR-y inverse agonist jointly discovered with AbbVie for the treatment of auto-immune diseases.
Due to the current COVID-19 context, the cedirogant Phase I clinical study in psoriasis patients led by AbbVie is now expected to read out in the second quarter of 2021 compared to the first quarter of 2021 as previously announced.

Main areas of progress in the R&D portfolio
Lanifibranor in non-alcoholic steatohepatitis (NASH)
 Launch of a collaboration with Professor Jérôme Boursier, M.D., Ph.D, Professor of Medicine at the Faculty of Medicine of Angers University, to develop one or several non-invasive biomarkers or a composite non-invasive biomarker score to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvement – February 25, 2021

 Finalization of the design of the pivotal Phase III clinical trial with lanifibranor in NASH following the receipt of the Scientific Advice letter from the EMA; confirmation of the initiation of the trial in the first half of 2021 – January 5, 2021

 Publication of new pre-clinical data on lanifibranor for the treatment of cirrhosis by the peer-reviewed scientific journal Journal of Hepatology, showing the beneficial effects of its mechanism of action on portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease (ACLD) – December 7, 2020

 Conclusions from Inventiva’s end-of-phase II meeting with the U.S. FDA for lanifibranor following the publication of positive topline results from its NATIVE Phase IIb clinical trial in NASH – November 10, 2020

 Receipt of the U.S. FDA “Breakthrough Therapy” designation for lanifibranor in NASH enabling the Company to expedite the development and review of the drug candidate – October 12, 2020

 Decision by Professor Kenneth Cusi, the investigator of the ongoing Phase II clinical trial evaluating lanifibranor in T2DM patients with NAFLD, to reduce the number of patients following higher than expected observed effects of lanifibranor in reducing steatosis during the NATIVE Phase IIb clinical trial in NASH – July 6, 2020

 Publication of positive topline results from the NATIVE Phase IIb clinical trial; decision to continue the clinical development of lanifibranor in NASH and enter into pivotal Phase III development – June 15, 2020

 Approval of a new patent protecting the use of lanifibranor for the treatment of several fibrotic diseases, including NASH, in China until June 2035 by the China National Intellectual Property Administration (CNIPA) – May 25, 2020

Odiparcil in mucopolysaccharidosis type VI (MPS VI)
 Decision to review all available options to optimize the development of second clinical-stage asset odiparcil for the treatment of MPS VI ; suspension of all MPS-related R&D activities during such time – November 10, 2020

 Receipt of the U.S. FDA “Fast Track” designation for odiparcil in MPS VI – October 19, 2020

 Acceptance of the “Investigational New Drug” (IND) application for odiparcil in MPS VI by the U.S. FDA – August 10, 2020

 Decision by Inventiva to extend the duration of the Phase I/II SAFE-KIDDS (SAFEty, pharmacoKInetics and pharmacoDynamics, Dose escalating Study) clinical trial evaluating odiparcil in MPS VI children from 6 to 12 months following a scientific advice meeting with the EMA – July 23, 2020

 Publication of latest data on odiparcil’s mechanism of action in the leading scientific journal PLOS ONE, showing that the drug candidate was associated with decreased glycosaminoglycan (GAG) accumulation and increased GAG excretion, and highlighting its distribution in MPS VI disease-relevant tissues and organs – May 18, 2020

Other significant milestones
 Opening of Inventiva’s subsidiary in the United States ahead of the initiation of the pivotal Phase III clinical trial with lanifibranor in NASH – January, 6, 2021

 Appointment of Dr. Michael Cooreman, M.D., as Inventiva’s Chief Medical Officer to succeed Dr. Marie-Paule Richard, M.D., who has decided to take her retirement as of December 17, 2020 – November 5, 2020

 Appointment of Dr. Arun J. Sanyal to Inventiva’s Scientific Advisory Board, further strengthening the Board’s expertise in the field of NASH – July 29, 2020

 Successful €94.96 million IPO on the Nasdaq Global Market in the United States, extending Inventiva’s cash runway through the fourth quarter of 2022 – July 15, 2020

 Entry into a €10.0 million non-dilutive loan facility guaranteed by the French State ("Prêt Garanti par l’Etat"), with the support of Bpifrance, Crédit Agricole Champagne-Bourgogne and Société Générale, contributing to strengthening the Company's cash position in the context of the COVID-19 pandemic – May 19, 2020

 Capital increase of €15 million subscribed by BVF Partners L.P., New Enterprise Associates (NEA), Novo Holdings A/S and Sofinnova Partners – February 11, 2020

Next key milestones expected
 Initiation of NATIV3 Phase III clinical trial evaluating lanifibranor in NASH – planned in the first half of 2021

 AbbVie’s completion of its ongoing Phase I clinical trial with cedirogant (ABBV-157) in psoriasis patients – expected in the second quarter of 2021

 Strategy update on the development of odiparcil – planned in 2021

Upcoming investor conference participation
 H.C. Wainwright Virtual Global Life Sciences Conference, March 9-10, 2021
 33rd Virtual Roth Conference, March 15-17, 2021
 7th Annual Truist Securities 2021 Life Sciences Summit, May 4-5, 2021
 Jefferies Virtual Healthcare Conference, June 1-3, 2021

Upcoming scientific conference participation
§ International Liver Congress™ 2021, June 23-26, 2021

Conference call
A conference call in English will be held tomorrow, Friday, March 5, 2021 at 2:00 pm (Paris time). To join the conference call, please use the code 3586531 after dialing one of the following numbers:
France: +33 (0) 1 70 70 07 81
Belgium: +32 (0) 2 793 3847
Germany: +49 (0) 69 2222 2625
Netherlands: +31 (0) 20 795 6614
Switzerland: +41 (0) 44 580 7145
United Kingdom: +44 (0) 207 192 8338
United States: +1 646-741-3167
The presentation accompanying this conference call will be available on Inventiva’s website from 2:00 pm (Paris time) tomorrow, Friday, March 5, 2021 onwards in the “Investors” – “Financial Results & Presentations” section and can be followed live at: https://edge.media-server.com/mmc/p/wr8srgzq.
A replay of the conference call and the presentation will be available after the event at: http://inventivapharma.com/investors/fi ... entations/.


Next financial results publication
§ Revenues and cash position for the first quarter of 2021: Thursday, May 13, 2021 (after U.S. market close)

rest van blabla is ingekort.

Grtz,
Terugnajaren
Gekko liked last!

Gebruikersavatar
Lama Daila
Forum elite
Forum elite
Berichten: 2327
Lid geworden op: 20 jul 2017 10:53
waarderingen: 4497
Contacteer:

Re: Inventiva Pharma

Bericht door Lama Daila »

Voornaamste boodschap lijkt me de timeline voor de fase3 studie:

Announcement of the timeline for the Phase III clinical trial with lanifibranor in NASH
Inventiva is progressing on the initiation of its NATIV3 (NASH lanifibranor Phase 3 trial) Phase III clinical trial evaluating lanifibranor in NASH, and has defined the following timeline for Part 1 of the study5:
 First site active – expected for the second quarter of 2021
 First Patient First Visit – expected in the third quarter of 2021
 Last Patient First Visit – expected in the second half of 2022
 Last Patient Last Visit – expected in the first half of 2024
 Publication of headline results – expected in the second half of 2024
NewB76 liked last!
https://twitter.com/lama_daila

Terugnajaren
Forum actieveling
Forum actieveling
Berichten: 302
Lid geworden op: 19 jul 2019 13:50
waarderingen: 383
Contacteer:

Re: Inventiva Pharma

Bericht door Terugnajaren »

KBC - Let's go nuts schreef in haar dagelijkse nieuwsbrief het volgende;

"• Inventiva meldt in haar 2020 update dat initiële tussentijdse resultaten van haar fase III NATIV3 studie met Lanifibranor in F2/F3 NASH te verwachten zijn in de tweede helft van 2024. Dat is waarschijnlijk te wijten aan trage NASH patiëntenrekrutering (gelet op de concurrentie en Covid-19). Operationeel werd in 2020 4,9 miljoen euro aan onderzoeksbelastingkredieten geboekt en daalden de uitgaven voor onderzoek en ontwikkeling met 29% tot 23,7 miljoen euro. "

Opletten dus dat het voorlopig alleen dragen van Fase III (zonder partner dus) in combinatie met moeilijkere werving niet leidt tot vervroegde druk op de cashpositie en verder uitlopen van planning.

Grtz,
Terugnajaren


Deelnemen aan het forum + meer functies?

Deel kennis en vragen met duizenden beleggers,
minder advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen 1 minuut!



Plaats reactie